


# Cautare in Registrul Comunitar

## Pasul 1 – Accesare Registrul Comunitar



European Commission > Live, work, travel in the EU >


Public Health - Union Register of medicinal products [Union Register support](#)

Union Register of medicinal products for human use

Search:

EU #	Brand name	Marketing Authorisation Holder
EU/1/14/944	Abasaglar	Eli Lilly Nederland B.V.
EU/1/21/1539	Abecma	Bristol-Myers Squibb Pharma EEIG
EU/1/20/1515	Abevmy	Biosimilar Collaborations Ireland Limited
EU/1/04/276	Ablify	Otsuka Pharmaceutical Netherlands B.V.
EU/1/13/882	ABILIFY MAINTENA	Otsuka Pharmaceutical Netherlands B.V.
EU/1/20/1512	Abiraterone Accord	Accord Healthcare S.L.U.

## Pasul 2 – Cautare denumire medicament in Registrul Comunitar



European Commission > Live, work, travel in the EU >

Public Health - Union Register of medicinal products [Union Register support](#)

Union Register of medicinal products for human use

Search:

EU #	Brand name	Marketing Authorisation Holder
EU/1/00/150	Actos	CHEPLAPHARM Arzneimittel GmbH

1 entries displayed from a total of 1,376. [Previous](#)  [Next](#)

Last updated on 11/03/2024.

Public Health [Follow us: Twitter](#) [DG Health and Food Safety](#)

## Pasul 3 – Detalii medicament



European Commission > Live, work, travel in the EU >

Public Health - Union Register of medicinal products [Union Register support](#)

Union Register of medicinal products for human use

Search:

EU #	Brand name	Marketing Authorisation Holder
EU/1/00/150	Actos	CHEPLAPHARM Arzneimittel GmbH

1 entries displayed from a total of 1,376. [Previous](#)  [Next](#)

Last updated on 11/03/2024.

Public Health [Follow us: Twitter](#) [DG Health and Food Safety](#)

## Pasul 4 – Afisarea detaliilor despre medicament



European Commission > Live, work, travel in the EU >

Public Health - Union Register of medicinal products

Union Register support

Union Register of medicinal products for human use

### Product information



Product name:	Actos	ACTIVE
EU number:	EU/1/00/150	
Active substance:	pioglitazone	
Indication:	Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as <u>monotherapy</u> - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as <u>dual oral therapy</u> in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient	

## Pasul 5 – Defilarea pana la ultima parte din josul paginii unde se afla ultima actualizare a anexelor

Updated with: Decision (2019)4325 of 06 Jun 2019

11 Jun 2019	PSUSA - Modification	EMEA/H/C/285/PSUSA/2417/201807	(2019)4325 of 06 Jun 2019				
04 Feb 2021	Centralised - Variation	EMEA/H/C/000285/WS1979/0084/G	-				

Updated with: Decision (2021)5672 of 23 Jul 2021

28 Jul 2021	Centralised - Transfer Marketing Authorisation Holder	EMEA/H/C/000285/T/0085	(2021)5672 of 23 Jul 2021				
11 Aug 2023	Centralised - Variation	EMEA/H/C/000285/IA/0088/G	-				

Last updated on 10/01/2024.

Public Health

Follow us: Twitter

DG Health and Food Safety

European Commission


Follow the European Commission

European Union

[Commission and its priorities](#)  
[Policies, information and services](#)

Facebook Twitter  
[Other social media](#)

[EU institutions](#)  
[European Union](#)



## Pasul 6 – Se va deschide automat fisierul PDF cu anexa

